Compare SiTime Corporation (SITM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SiTime Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? SiTime Corporation trades at $510 (market cap $15.76B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: SiTime Corporation is far larger — about 2.1× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SiTime Corporation for 18 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SITM | SYRE | |
|---|---|---|
Market Cap | $15.76B | $7.35B |
Volume | 697,177 | 1,624,631 |
Sector | Technology | Health |
52-Week High | $901.60 | $108.92 |
52-Week Low | $252.76 | $22.18 |
Typical Hold Time | 18 Days | 0 Days |
Enterprise Value | $15.17B | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SITM trades at $579.66, up 1.68% today, showing strong momentum after recent earnings beats. The stock faces technical headwinds with bearish moving averages but benefits from unanimous analyst buy ratings and a $751.43 consensus price target. Recent Q2 2026 results showed 126.5% revenue growth to $157.43M and the company's first GAAP profit, driven by AI infrastructure demand and the Renesas acquisition.
The outlook remains positive with accelerating AI-driven growth, though high valuations (P/E 966.1) and negative 2025 net income ($-42.9M) pose risks. Institutional buying and strong Q3 guidance support upside potential, but investors should monitor execution on margin expansion and competitive pressures in the timing solutions market.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
